Home LiteratureArticle Details
PMID: 21484577 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

AMP-activated protein kinase and metabolic control.

Handbook of experimental pharmacology ·No. 203 ·2011-00-00 ·Pages 303-30

Viollet B, Andreelli F

Abstract

AMP-activated protein kinase AMP-activated protein kinase (AMPK AMPK ), a phylogenetically conserved serine/threonine protein kinase, is a major regulator of cellular and whole-body energy homeostasis that coordinates metabolic pathways in order to balance nutrient supply with energy demand. It is now recognized that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile, and blood pressure in insulin-resistant rodents. Indeed, AMPK activation mimics the beneficial effects of physical activity or those of calorie restriction calorie restriction by acting on multiple cellular targets. In addition, it is now demonstrated that AMPK is one of the probable (albeit indirect) targets of major antidiabetic drugs drugs including the biguanides (metformin metformin ) and thiazolidinedione thiazolidinedione s, as well as of insulin-sensitizing adipokines (e.g., adiponectin adiponectin ). Taken together, such findings highlight the logic underlying the concept of targeting the AMPK pathway for the treatment of metabolic syndrome and type 2 diabetes.

MeSH Terms
Anti-Obesity Agents/pharmacology,therapeutic use Caloric Restriction Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors,metabolism Endothelium, Vascular/drug effects,physiology Enzyme Inhibitors/pharmacology,therapeutic use Exercise/physiology Humans Hypoglycemic Agents/pharmacology,therapeutic use Hypolipidemic Agents/pharmacology,therapeutic use Myocardial Ischemia/drug therapy
Chemicals
Anti-Obesity Agents Enzyme Inhibitors Hypoglycemic Agents Hypolipidemic Agents Cyclic AMP-Dependent Protein Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Viollet Benoit
Inserm, U1016, Institut Cochin, Paris, France. benoit.viollet@inserm.fr
Andreelli Fabrizio
References (190)
190 references, click to expand
  1. 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes.
    Diabetes. 2003 May;52(5):1066-72 PMID: 12716734
  2. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise.
    Diabetes. 2001 May;50(5):921-7 PMID: 11334434
  3. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle.
    Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E1062-8 PMID: 17666490
  4. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
    Nature. 2007 Nov 29;450(7170):712-6 PMID: 18046409
  5. AMP-activated protein kinase plays a role in the control of food intake.
    J Biol Chem. 2004 Mar 26;279(13):12005-8 PMID: 14742438
  6. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.
    Diabetologia. 2008 Oct;51(10):1893-900 PMID: 18709353
  7. Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin.
    FEBS Lett. 2005 Sep 12;579(22):5049-54 PMID: 16137686
  8. Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia.
    Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2875-83 PMID: 16877552
  9. Long-term AICAR administration and exercise prevents diabetes in ZDF rats.
    Diabetes. 2005 Apr;54(4):928-34 PMID: 15793229
  10. Plasma adiponectin levels and risk of myocardial infarction in men.
    JAMA. 2004 Apr 14;291(14):1730-7 PMID: 15082700
  11. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.
    Nat Med. 2005 Oct;11(10):1096-103 PMID: 16155579
  12. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes.
    J Biol Chem. 2005 Jul 1;280(26):25250-7 PMID: 15878856
  13. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
    Circulation. 1986 Nov;74(5):1124-36 PMID: 3769170
  14. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression.
    Diabetes Res Clin Pract. 2006 Aug;73(2):135-42 PMID: 16503364
  15. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.
    J Biol Chem. 2002 Jul 12;277(28):25226-32 PMID: 11994296
  16. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects.
    Diabetes Care. 2006 Jun;29(6):1337-44 PMID: 16732018
  17. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression.
    Biochem J. 2003 May 1;371(Pt 3):761-74 PMID: 12589707
  18. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.
    Diabetes. 2001 Sep;50(9):2094-9 PMID: 11522676
  19. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
    Diabetes. 2008 Dec;57(12):3211-21 PMID: 18796617
  20. Identification and role of the basal phosphorylation site on hormone-sensitive lipase.
    Eur J Biochem. 1990 Jul 20;191(1):245-50 PMID: 2165906
  21. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.
    Nature. 2003 Sep 11;425(6954):191-6 PMID: 12939617
  22. Expression of the uncoupling protein 1 from the aP2 gene promoter stimulates mitochondrial biogenesis in unilocular adipocytes in vivo.
    Eur J Biochem. 2002 Jan;269(1):19-28 PMID: 11784294
  23. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes.
    J Biol Chem. 1998 Jun 12;273(24):14767-71 PMID: 9614076
  24. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.
    Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11513-8 PMID: 10500208
  25. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin.
    Endocrinology. 2006 May;147(5):2432-41 PMID: 16455782
  26. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone.
    Biochem Biophys Res Commun. 2006 May 12;343(3):700-6 PMID: 16563350
  27. Insulin signalling and the regulation of glucose and lipid metabolism.
    Nature. 2001 Dec 13;414(6865):799-806 PMID: 11742412
  28. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway.
    Endocrinology. 2008 Sep;149(9):4510-8 PMID: 18511510
  29. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Diabetes Care. 2009 Jan;32(1):193-203 PMID: 18945920
  30. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.
    Diabetes. 1995 Aug;44(8):863-70 PMID: 7621989
  31. AMP-activated protein kinase phosphorylation of endothelial NO synthase.
    FEBS Lett. 1999 Jan 29;443(3):285-9 PMID: 10025949
  32. Role of AMP-activated protein kinase in mechanism of metformin action.
    J Clin Invest. 2001 Oct;108(8):1167-74 PMID: 11602624
  33. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.
    Cell. 2006 Dec 15;127(6):1109-22 PMID: 17112576
  34. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance.
    Diabetes Care. 2003 Aug;26(8):2341-4 PMID: 12882859
  35. Hepatic 5'-AMP-activated protein kinase: zonal distribution and relationship to acetyl-CoA carboxylase activity in varying nutritional states.
    Arch Biochem Biophys. 1994 Feb 1;308(2):413-9 PMID: 7906505
  36. Effect of AMPK activation on muscle glucose metabolism in conscious rats.
    Am J Physiol. 1999 May;276(5):E938-44 PMID: 10329989
  37. AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic beta-cells without changing triglyceride levels.
    J Mol Endocrinol. 2008 Sep;41(3):187-94 PMID: 18579684
  38. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?
    Eur J Biochem. 1995 Apr 15;229(2):558-65 PMID: 7744080
  39. AMPK regulates basal skeletal muscle capillarization and VEGF expression, but is not necessary for the angiogenic response to exercise.
    J Physiol. 2008 Dec 15;586(24):6021-35 PMID: 18955383
  40. Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice.
    Diabetes. 2008 Nov;57(11):2958-66 PMID: 18728234
  41. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro.
    J Biol Chem. 1998 Jan 2;273(1):215-21 PMID: 9417067
  42. The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells.
    FEBS Lett. 1998 Nov 20;439(3):287-90 PMID: 9845339
  43. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B.
    Cell Metab. 2007 Oct;6(4):307-19 PMID: 17908559
  44. Mechanisms linking obesity with cardiovascular disease.
    Nature. 2006 Dec 14;444(7121):875-80 PMID: 17167476
  45. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase.
    Diabetes. 2000 Jun;49(6):896-903 PMID: 10866040
  46. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue.
    Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E500-8 PMID: 16188906
  47. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols.
    Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13632-7 PMID: 17698806
  48. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.
    Cardiovasc Res. 2005 Sep 1;67(4):705-13 PMID: 15907819
  49. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase.
    Diabetes. 2006 Feb;55(2):496-505 PMID: 16443786
  50. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes.
    Diabetes. 2002 Dec;51 Suppl 3:S405-13 PMID: 12475783
  51. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue.
    Biochem Biophys Res Commun. 2004 Apr 9;316(3):853-8 PMID: 15033479
  52. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.
    Diabetes Care. 2009 Nov;32 Suppl 2:S157-63 PMID: 19875544
  53. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models.
    Biochem Soc Trans. 2003 Feb;31(Pt 1):216-9 PMID: 12546688
  54. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats.
    Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E794-800 PMID: 15956049
  55. AMPK alterations in cardiac physiology and pathology: enemy or ally?
    J Physiol. 2006 Jul 1;574(Pt 1):95-112 PMID: 16690706
  56. AMPK in Health and Disease.
    Physiol Rev. 2009 Jul;89(3):1025-78 PMID: 19584320
  57. Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretion.
    Diabetes. 2002 Dec;51 Suppl 3:S414-20 PMID: 12475784
  58. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15983-7 PMID: 12444247
  59. Defining and characterizing the progression of type 2 diabetes.
    Diabetes Care. 2009 Nov;32 Suppl 2:S151-6 PMID: 19875543
  60. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome.
    Diabetes. 2002 Jul;51(7):2199-206 PMID: 12086950
  61. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle.
    J Appl Physiol (1985). 2000 Jun;88(6):2219-26 PMID: 10846039
  62. Acute exercise increases nitric oxide synthase activity in skeletal muscle.
    Am J Physiol. 1999 Aug;277(2):E390-4 PMID: 10444436
  63. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion.
    Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1023-31 PMID: 14871885
  64. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo.
    J Endocrinol. 2005 Nov;187(2):225-35 PMID: 16293770
  65. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.
    J Biol Chem. 2010 Mar 12;285(11):8340-51 PMID: 20061378
  66. The 5'-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex.
    FEBS Lett. 1998 Jul 17;431(2):180-4 PMID: 9708898
  67. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes.
    Am J Physiol. 1999 Jul;277(1):E1-10 PMID: 10409121
  68. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.
    Nature. 2009 Apr 23;458(7241):1056-60 PMID: 19262508
  69. Mechanisms of beta-cell death in type 2 diabetes.
    Diabetes. 2005 Dec;54 Suppl 2:S108-13 PMID: 16306327
  70. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase.
    J Biol Chem. 2006 Oct 27;281(43):32207-16 PMID: 16943194
  71. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target.
    Biochem J. 1999 Mar 15;338 ( Pt 3):783-91 PMID: 10051453
  72. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats.
    Life Sci. 2006 Apr 25;78(22):2615-24 PMID: 16318863
  73. nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle.
    Physiol Genomics. 2000 Jan 24;2(1):21-7 PMID: 11015578
  74. Regulation of fasted blood glucose by resistin.
    Science. 2004 Feb 20;303(5661):1195-8 PMID: 14976316
  75. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.
    Nature. 2002 Jan 17;415(6869):339-43 PMID: 11797013
  76. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus.
    Nature. 2004 Apr 1;428(6982):569-74 PMID: 15058305
  77. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise.
    Biochem Biophys Res Commun. 2004 Jul 23;320(2):449-54 PMID: 15219849
  78. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.
    Diabetes. 2006 Oct;55(10):2688-97 PMID: 17003332
  79. AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle.
    J Physiol. 2005 Jun 1;565(Pt 2):547-53 PMID: 15774529
  80. AS160 phosphorylation is associated with activation of alpha2beta2gamma1- but not alpha2beta2gamma3-AMPK trimeric complex in skeletal muscle during exercise in humans.
    Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E715-22 PMID: 17077344
  81. Resistance exercise increases human skeletal muscle AS160/TBC1D4 phosphorylation in association with enhanced leg glucose uptake during postexercise recovery.
    J Appl Physiol (1985). 2008 Dec;105(6):1967-74 PMID: 18845784
  82. Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport.
    Diabetes. 1998 Aug;47(8):1369-73 PMID: 9703344
  83. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism.
    Eur J Biochem. 1989 Jan 15;179(1):249-54 PMID: 2537200
  84. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase.
    Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2488-94 PMID: 16224049
  85. AMPK and PPARdelta agonists are exercise mimetics.
    Cell. 2008 Aug 8;134(3):405-15 PMID: 18674809
  86. Progressive increase in human skeletal muscle AMPKalpha2 activity and ACC phosphorylation during exercise.
    Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E688-94 PMID: 11832374
  87. Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells.
    J Biol Chem. 2005 May 6;280(18):17608-16 PMID: 15753079
  88. Rapid transformation of white adipocytes into fat-oxidizing machines.
    Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2058-63 PMID: 14769942
  89. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation.
    Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1202-6 PMID: 11052978
  90. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.
    Biochem Biophys Res Commun. 2004 Feb 6;314(2):580-5 PMID: 14733947
  91. Guidelines for healthy weight.
    N Engl J Med. 1999 Aug 5;341(6):427-34 PMID: 10432328
  92. New diagnostic criteria and classification of diabetes--again?
    Diabet Med. 1998 Jul;15(7):535-6 PMID: 9686691
  93. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.
    J Biol Chem. 2003 Jan 24;278(4):2461-8 PMID: 12431986
  94. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.
    Diabetes. 2001 May;50(5):1076-82 PMID: 11334411
  95. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice.
    Cell Metab. 2005 Aug;2(2):105-17 PMID: 16098828
  96. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats.
    Diabetes. 2002 Oct;51(10):2886-94 PMID: 12351423
  97. Disruption of adiponectin causes insulin resistance and neointimal formation.
    J Biol Chem. 2002 Jul 19;277(29):25863-6 PMID: 12032136
  98. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling.
    J Biol Chem. 2004 Jul 2;279(27):28670-4 PMID: 15123726
  99. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle.
    Diabetes. 2007 Jun;56(6):1630-7 PMID: 17363741
  100. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists.
    J Biol Chem. 2006 Feb 3;281(5):2654-60 PMID: 16326714
  101. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
    Biochem Biophys Res Commun. 2005 Jul 8;332(3):885-91 PMID: 15913551
  102. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection.
    Cardiovasc Res. 2004 Feb 15;61(3):610-9 PMID: 14962491
  103. Resveratrol improves health and survival of mice on a high-calorie diet.
    Nature. 2006 Nov 16;444(7117):337-42 PMID: 17086191
  104. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase.
    Mol Cell Biol. 2007 Jun;27(12):4317-27 PMID: 17420279
  105. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function.
    J Am Coll Cardiol. 2008 Sep 16;52(12):1006-12 PMID: 18786482
  106. Role of adenosine 5'-monophosphate-activated protein kinase in interleukin-6 release from isolated mouse skeletal muscle.
    Endocrinology. 2009 Feb;150(2):600-6 PMID: 18818284
  107. Acute stimulation of glucose metabolism in mice by leptin treatment.
    Nature. 1997 Sep 25;389(6649):374-7 PMID: 9311777
  108. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.
    Nat Genet. 2003 Jul;34(3):267-73 PMID: 12808457
  109. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle.
    Cell Metab. 2010 Mar 3;11(3):213-9 PMID: 20197054
  110. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633.
    Circ Res. 2009 Feb 27;104(4):496-505 PMID: 19131647
  111. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1.
    Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3820-5 PMID: 11274399
  112. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.
    Nature. 2004 Jun 17;429(6993):771-6 PMID: 15175761
  113. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?
    Exerc Sport Sci Rev. 2005 Jul;33(3):114-9 PMID: 16006818
  114. Mitochondrial dysfunction in the elderly: possible role in insulin resistance.
    Science. 2003 May 16;300(5622):1140-2 PMID: 12750520
  115. AMP kinase is not required for the GLUT4 response to exercise and denervation in skeletal muscle.
    Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E739-43 PMID: 15165992
  116. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity.
    Diabetes Care. 2001 Jan;24(1):117-23 PMID: 11194216
  117. Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle.
    J Appl Physiol (1985). 1999 Nov;87(5):1990-5 PMID: 10562646
  118. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
    N Engl J Med. 2001 May 3;344(18):1343-50 PMID: 11333990
  119. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism.
    Nature. 2005 Oct 20;437(7062):1109-11 PMID: 16148943
  120. Limb blood flow during exercise is dependent on nitric oxide.
    Circulation. 1998 Jul 28;98(4):369-74 PMID: 9711943
  121. Type 2 diabetes-a matter of beta-cell life and death?
    Science. 2005 Jan 21;307(5708):380-4 PMID: 15662003
  122. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise.
    J Biol Chem. 2002 Sep 6;277(36):32571-7 PMID: 12065578
  123. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.
    Am J Physiol. 1997 Dec;273(6):E1107-12 PMID: 9435525
  124. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
    Diabetes Care. 1997 Apr;20(4):537-44 PMID: 9096977
  125. UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase.
    Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E622-9 PMID: 10950831
  126. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
    Nat Med. 2000 Sep;6(9):998-1003 PMID: 10973319
  127. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.
    Hepatology. 2003 May;37(5):1202-19 PMID: 12717402
  128. 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle.
    Diabetes. 1999 Aug;48(8):1667-71 PMID: 10426389
  129. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death.
    Endocrinology. 2003 Sep;144(9):4154-63 PMID: 12933690
  130. Possible involvement of AMP-activated protein kinase in obesity resistance induced by respiratory uncoupling in white fat.
    FEBS Lett. 2004 Jul 2;569(1-3):245-8 PMID: 15225642
  131. Mechanisms linking obesity to insulin resistance and type 2 diabetes.
    Nature. 2006 Dec 14;444(7121):840-6 PMID: 17167471
  132. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells.
    J Biol Chem. 2008 Oct 10;283(41):27452-27461 PMID: 18693249
  133. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade.
    Biochem J. 2007 Apr 1;403(1):139-48 PMID: 17147517
  134. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.
    J Biol Chem. 2005 Jul 1;280(26):25196-201 PMID: 15899896
  135. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation.
    J Biol Chem. 2008 Oct 10;283(41):27628-27635 PMID: 18687677
  136. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase.
    Diabetologia. 2003 Feb;46(2):250-4 PMID: 12627324
  137. The 5'-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle.
    J Biol Chem. 2004 Sep 10;279(37):38441-7 PMID: 15247217
  138. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver.
    Diabetes. 2005 May;54(5):1331-9 PMID: 15855317
  139. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.
    Nat Med. 2002 Nov;8(11):1288-95 PMID: 12368907
  140. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16309-13 PMID: 12456889
  141. Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo.
    Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1399-408 PMID: 20200137
  142. SirT1 gain of function increases energy efficiency and prevents diabetes in mice.
    Cell Metab. 2008 Oct;8(4):333-41 PMID: 18840364
  143. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.
    J Clin Invest. 2003 Jul;112(1):91-100 PMID: 12840063
  144. Metabolic activation of AMP kinase in vascular smooth muscle.
    J Appl Physiol (1985). 2005 Jan;98(1):296-306 PMID: 15377643
  145. Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells.
    Life Sci. 2007 Jun 20;81(2):160-5 PMID: 17544010
  146. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver.
    EMBO J. 1990 Aug;9(8):2439-46 PMID: 2369897
  147. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle.
    FASEB J. 2005 Jul;19(9):1146-8 PMID: 15878932
  148. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
    Obes Res. 2002 Oct;10(10):1008-15 PMID: 12376581
  149. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects.
    Diabetes. 2005 Nov;54(11):3154-60 PMID: 16249439
  150. Resveratrol stimulates AMP kinase activity in neurons.
    Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7217-22 PMID: 17438283
  151. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin.
    Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E18-23 PMID: 11739078
  152. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus.
    J Pediatr Endocrinol Metab. 2003 Jan;16(1):5-22 PMID: 12585335
  153. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
    N Engl J Med. 2002 Feb 7;346(6):393-403 PMID: 11832527
  154. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.
    Nat Med. 2001 Aug;7(8):941-6 PMID: 11479627
  155. Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity.
    Diabetes. 2008 Feb;57(2):415-23 PMID: 18003756
  156. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
    Diabetes. 1995 Nov;44(11):1249-58 PMID: 7589820
  157. Lipotoxicity in human pancreatic islets and the protective effect of metformin.
    Diabetes. 2002 Feb;51 Suppl 1:S134-7 PMID: 11815472
  158. AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle.
    Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1239-48 PMID: 12388122
  159. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice.
    Diabetes. 2006 Aug;55(8):2180-91 PMID: 16873680
  160. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase.
    Diabetes. 2001 Jul;50(7):1515-21 PMID: 11423471
  161. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.
    Circulation. 2001 Feb 27;103(8):1057-63 PMID: 11222466
  162. Adiponectin-mediated modulation of hypertrophic signals in the heart.
    Nat Med. 2004 Dec;10(12):1384-9 PMID: 15558058
  163. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha.
    Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12017-22 PMID: 17609368
  164. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.
    J Clin Invest. 2004 Aug;114(4):495-503 PMID: 15314686
  165. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Diabetes. 2003 Mar;52(3):667-74 PMID: 12606507
  166. The metabolic syndrome.
    Lancet. 2005 Apr 16-22;365(9468):1415-28 PMID: 15836891
  167. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase.
    J Biol Chem. 2007 Oct 12;282(41):30143-9 PMID: 17724029
  168. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1.
    Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12861-6 PMID: 17646659
  169. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling.
    Cell Metab. 2006 Dec;4(6):465-74 PMID: 17141630
  170. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase.
    J Mol Endocrinol. 2003 Apr;30(2):151-61 PMID: 12683939
  171. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis.
    Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1340-6 PMID: 11701451
  172. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial.
    Am J Clin Nutr. 2006 Nov;84(5):1033-42 PMID: 17093155
  173. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase.
    Mol Cell Biol. 2000 Sep;20(18):6704-11 PMID: 10958668
  174. AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis.
    Cell Signal. 2007 Apr;19(4):791-805 PMID: 17127032
  175. Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo.
    J Biol Chem. 2009 Sep 4;284(36):23925-34 PMID: 19525228
  176. AMPK, the metabolic syndrome and cancer.
    Trends Pharmacol Sci. 2005 Feb;26(2):69-76 PMID: 15681023
  177. Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells?
    J Biol Chem. 2005 Dec 16;280(50):41504-11 PMID: 16199527
  178. Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo.
    Diabetologia. 2010 May;53(5):924-36 PMID: 20221584
  179. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase.
    J Biol Chem. 2008 Jul 18;283(29):20015-26 PMID: 18482975
  180. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
    Cell Metab. 2006 Jun;3(6):403-16 PMID: 16753576
  181. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients.
    Diabetologia. 2008 Feb;51(2):309-19 PMID: 18080107
  182. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats.
    Diabetes. 1999 Feb;48(2):287-91 PMID: 10334303
  183. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase.
    FEBS Lett. 1994 Oct 10;353(1):33-6 PMID: 7926017
  184. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase.
    Nat Med. 2004 Jul;10(7):727-33 PMID: 15195087
  185. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells.
    PLoS Biol. 2006 Feb;4(2):e31 PMID: 16366736
  186. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
    Science. 2005 Dec 9;310(5754):1642-6 PMID: 16308421
  187. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
    Diabetes. 2003 Jan;52(1):102-10 PMID: 12502499
  188. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol.
    Diabetes. 2010 Mar;59(3):554-63 PMID: 19934007
  189. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice.
    Diabetologia. 2002 Jan;45(1):56-65 PMID: 11845224
  190. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle.
    J Biol Chem. 2006 Jul 14;281(28):18933-41 PMID: 16687413
Article Info
Journal
Handbook of experimental pharmacology
Abbr.
Handb Exp Pharmacol
ISSN
0171-2004
DOI
10.1007/978-3-642-17214-4_13
Email
benoit.viollet@inserm.fr
Published
2011-00-00
Pages
303-30
Language
English
Region
Germany
NLM ID
7902231
PMCID
PMC3384586
Subset
IM
External Links
PubMed source DOI: 10.1007/978-3-642-17214-4_13 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2